Teva UK launches generic eye treatment

CASTLEFORD, England The British subsidiary of Teva Pharmaceutical Industries has launched a treatment for intra-ocular pressure resulting from ocular hypertension, open-angle glaucoma and pseudo-exfoliative glaucoma, the generic drug maker announced Thursday.

Teva UK launched dorzolamide eye drops in the 2% strength, which is meant for use as an adjunctive therapy to beta blockers or for patients who have not responded to treatment with beta blockers.

The drug is a generic version of Trusopt, made by MSD in the United Kingdom and Merck & Co. in the United States.